Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2013 Oct 19.

Published in final edited form as: Cancer Gene Ther. 2009 Feb 20;16(9):673–682. doi: 10.1038/cgt.2009.17

(a) Mice were immunized with 0 (saline), 1, or 3 injections of a replicating Ad5 vector (Ad5[RC]) to induce differing levels of pre-existing anti-adenovirus immunity. The anti-Ad5 antibody endpoint titer was determined by ELISA. This data is representative of 4 experiments. (b) Anti-Ad T cell proliferative responses induced by a single administration of either saline, or Ad[E1+]CEA, Ad[E1−]CEA, or Ad[E1−, E2b−]CEA vectors in mice that had been preconditioned with 3 injections of Ad5[RC] vector.

(a) Mice were immunized with 0 (saline), 1, or 3 injections of a replicating Ad5 vector (Ad5[RC]) to induce differing levels of pre-existing anti-adenovirus immunity. The anti-Ad5 antibody endpoint titer was determined by ELISA. This data is representative of 4 experiments. (b) Anti-Ad T cell proliferative responses induced by a single administration of either saline, or Ad[E1+]CEA, Ad[E1−]CEA, or Ad[E1−, E2b−]CEA vectors in mice that had been preconditioned with 3 injections of Ad5[RC] vector.